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Abstract
Background: Cervical cancer is the most common cancer among Indian women. This cancer has well defined pre-
cancerous stages and evolves over 10-15 years or more. This study was undertaken to identify differentially
expressed genes between normal, dysplastic and invasive cervical cancer.
Materials and methods: A total of 28 invasive cervical cancers, 4 CIN3/CIS, 4 CIN1/CIN2 and 5 Normal cervix
samples were studied. We have used microarray technique followed by validation of the significant genes by
relative quantitation using Taqman Low Density Array Real Time PCR. Immunohistochemistry was used to study
the protein expression of MMP3, UBE2C and p16 in normal, dysplasia and cancers of the cervix. The effect of a
dominant negative UBE2C on the growth of the SiHa cells was assessed using a MTT assay.
Results: Our study, for the first time, has identified 20 genes to be up-regulated and 14 down-regulated in cervical
cancers and 5 up-regulated in CIN3. In addition, 26 genes identified by other studies, as to playing a role in
cervical cancer, were also confirmed in our study. UBE2C, CCNB1, CCNB2, PLOD2, NUP210, MELK, CDC20 genes
were overexpressed in tumours and in CIN3/CIS relative to both Normal and CIN1/CIN2, suggesting that they could
have a role to play in the early phase of tumorigenesis. IL8, INDO, ISG15, ISG20, AGRN, DTXL, MMP1, MMP3, CCL18,
TOP2A AND STAT1 were found to be upregulated in tumours. Using Immunohistochemistry, we showed over-
expression of MMP3, UBE2C and p16 in cancers compared to normal cervical epithelium and varying grades of
dysplasia. A dominant negative UBE2C was found to produce growth inhibition in SiHa cells, which over-expresses
UBE2C 4 fold more than HEK293 cells.
Conclusions: Several novel genes were found to be differentially expressed in cervical cancer. MMP3, UBE2C and
p16 protein overexpression in cervical cancers was confirmed by immunohistochemistry. These will need to be
validated further in a larger series of samples. UBE2C could be evaluated further to assess its potential as a
therapeutic target in cervical cancer.
Background
Cervical cancer is the second most common cancer
among women worldwide and the most common cancer
i nI n d i a nw o m e n[ 1 ] .I nm o s td e v e l o p i n gc o u n t r i e s
there are no organized screening programmes, as a
result most patients report to tertiary centres in locally
advanced stages.
Human papilloma viruses (HPV) have been shown to
play a major role in the pathogenesis of cervical cancer,
but it alone is not sufficient [2]. Additional events,
activation of proto-oncogenes and inactivation of
tumour suppressor genes, are required in the induction
of cervical cancer.
Cervical cancer goes through a series of pre-malignant
stages - Cervical Intraepithelial Neoplasia (CIN) 1, 2 and
3. In general it takes upto about 10 - 15 years for the
normal cervical epithelial cell to become a malignant
one. However, some CIN2 lesions may develop soon
after HPV infection, suggesting that there could be
alternate pathways involved. CIN1 and 2 have a higher
rate of spontaneous reversion compared to CIN3 [3].
The CIN3 then progresses to invasive carcinoma, which
can then metastasize to regional lymph nodes and dis-
tant organs (e.g. lung).
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study the expression patterns of more than 40,000 genes
at a time [4]. Several groups have used microarray based
technology to look for differentially expressed genes in
the different stages of cervical tumorigenesis [5,6].
Few studies have followed up and validated the microar-
ray data in a large number of genes [7,8]. The objective
of our study was to identify genes differentially
expressed between normal cervix, CIN1/CIN2, CIN3/
CIS and invasive cervical cancer, using oligo-microarray
technique, validate the genes so identified using Relative
quantitation Real Time Polymerase Chain Reaction
(RQ-RT-PCR) and detect potential biomarkers for early
diagnosis and therapeutic targets.
Methods
Archival total RNA extracted from punch biopsy sam-
ples from patients with cervical cancer, collected in
RNA later (Ambion, Austin, USA; Cat no: AM7021) and
stored in the tumour bank after an informed consent
were used, after obtaining the Institutional Ethical com-
mittee’s approval for the study. The RNA had been
extracted from the biopsy samples using the RNeasy
RNA extraction kit (Qiagen, Gmbh, Hilden; Cat no:
74106) as per the manufacturer’s instructions.
Twenty eight cervical cancer patients’ samples were
included in the study. The criteria for inclusion in the
s t u d yw e r ea sf o l l o w s :1 .g o o dq u a l i t yR N Aa sa s s e s s e d
by Bio-analyser (RIN 6 or above); 2. paired paraffin
block having at least 70% tumour cells; 3. sufficient
quantity of RNA be available; 4. patient should have
completed prescribed radiotherapy and follow-up
information till death/last disease free status be
available.
In addition, 5 normal cervix tissues from women who
underwent hysterectomy for non-malignant conditions
or for non-cervical cancer were included. Four CIN1/
CIN2 and 4 CIN3/CIS (one CIN3/CIS was included for
RQ-RT-PCR analysis directly) were also included after
informed consent. The Normal and CIN samples under-
went frozen section to confirm their histopathologic sta-
tus and the samples were immediately snap frozen in
liquid nitrogen. RNA was extracted from the samples
using the RNeasy RNA extraction kit, as described
above.
HPV Testing
The quality of the DNA was assessed by amplifying for
b globin and only then HPV testing was done using
GP5+ and GP6+ primers [9]. HPV16 and 18 typing was
done using Nested Multiplex Polymerase Chain Reac-
tion (NMPCR) technique [10]. SiHa DNA for HPV16
and HeLa DNA for HPV18 (positive controls) and
C33A DNA (negative control) were included in all runs.
Microarray experiment
1 μg of total RNA from the tumour/CIN/Normal sample
and universal RNA (Stratagene; Cat no: 740000-41) were
reverse transcribed using Arrayscript at 42°C for 2 hrs
to obtain cDNA using the Amino Allyl MessageAmp II
aRNA amplification kit (Ambion, Austin, USA; Cat no:
AM1797). The cDNA was amplified by in-vitro tran-
scription in the presence of T7 RNA polymerase; aRNA
thus obtained was purified and quantitated in NanoDrop
(NanoDrop Technologies, Wilmington, DE, USA). 20 μg
of tumour/CIN/Normal aRNA was labelled using NHS
ester of Cy5 dye and the control universal aRNA was
labelled using NHS ester of C y 3d y e .T h eC y 3a n dC y 5
labelled aRNA was used for hybridization onto the
microarray chips from Stanford Functional Genomics
Facility (SFGF, Stanford, CA) containing 44,544 spots,
for 16 hrs in Lucidea SlidePro hybridization chamber
(GE Health Care, Uppsala, Sweden) at 42°C. After hybri-
dization, slides were washed in 0.1× SSC, 1× SSC fol-
lowed by 0.1× SSC and dried.
The slides were scanned in ProScanArray (PerkinEl-
mer, Shelton, CT, USA). Griding was done using Scan
array Express software package (version -4). The inte-
grated or mean intensity of signal within the spot was
calculated. The files were saved as GPR files.
All the raw data files have been submitted to GEO
with an assigned GEO accession number - GSE14404.
Microarray dasta analysis
The Foreground Median intensity for Cy3 and Cy5,
Background Median intensity for Cy3 and Cy5, spot size
data were imported into BRB-ArrayTools software [11]
using the Import wizard function. Background correc-
tion was not done. Global normalization was used to
median centre the log-ratios on each array in order to
adjust for differences in labelling intensities of the Cy3
and Cy5 dyes. The data was analysed using the Class
comparison and Class prediction modules in the BRB-
Array Tools software. In addition, Lowess normalization
w a sa l s od o n es e p a r a t e l ya n dt h ed a t aa n a l y s e du s i n g
the modules mentioned above. The normalized Log
ratios were also imported into Significance Analysis of
Microarray (SAM) [12] software and analysed.
Class Comparison in BRB-Array Tools
We identified genes that were differentially expressed
among the four classes (Normal, CIN1/2, CIN3/CIS,
Cancer) using a random-variance t-test. The random-
variance t-test is an improvement over the standard
separate t-test as it permits sharing information among
genes about within-class variation without assuming
that all genes have the same variance [13]. Genes were
considered statistically significant if their p value was
< 0.01. In addition a two fold difference was required
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mal, CIN1/2 and Normal. The same was repeated with
the Lowess normalized data using the same criteria.
Class prediction in BRB-Array Tools
We developed models for utilizing gene expression pro-
file to predict the class of future samples based on the
Diagonal Linear Discriminant Analysis and Nearest
Neighbour Classification [11]. The models incorporated
genes that were differentially expressed among genes at
the 0.01 significance level as assessed by the random
variance t-test [13]. We estimated the prediction error
of each model using leave-one-out cross-validation
(LOOCV) as described [14]. Leave-one-out cross-valida-
tion method was used to compute mis-classification
rate. From the list, genes were sorted further based on 2
fold difference between Cancer versus CIN1/2 & Nor-
mal, CIN3/CIS versus CIN1/2 & Normal, and CIN1/2
versus Normal. The same was repeated with the Lowess
normalized data using a significance value of 0.01.
SAM Analysis
The normalized log ratios of all the samples were
imported into SAM software and analysed. A Multi-
class analysis with 100 permutations was done. A delta
v a l u eo f0 . 9 6a n daf o l dd i f f e r e n c eo f2w a su s e dt o
identify the genes differentially expressed.
Quantitative Real time PCR
High Capacity Reverse Transcription kit (Applied Bio-
systems, Foster City, CA; Cat no: 4368814) was used to
reverse transcribe 2 μgo ft o t a lR N Af r o mt h e3 8s a m -
ples in a 20 μl reaction volume. In 3 samples, due to the
limiting amount of RNA, 0.75 μg was used for the
cDNA synthesis.
These cDNA samples were used for real time PCR
amplification assays using TaqMan
® arrays formerly
TaqMan
® Low density arrays (TLDA) (Applied Biosys-
tems, Foster City, CA; Cat no: 4342261). The fluoro-
genic, FAM labelled probes and the sequence specific
primers for the list of genes with endogenous control
18S rRNA were obtained as inventoried assays and
incorporated into the TaqMan
® array format. Quadru-
plicate (n = 38) and duplicate (n = 3; with limiting
amount of RNA for cDNA synthesis) cDNA template
samples were amplified and analysed on the ABI Prism
7900HT sequence detection system (Applied Biosystems,
Foster City, CA).
The reaction set up, briefly, consisted of 1.44 μgo f
cDNA template made up to 400 μl with deionised water
and equal amounts of TaqMan
® Universal PCR Master
Mix (Applied Biosystems, Foster City, CA; Cat no:
4304437). 100 μl was loaded into each of the 8 ports of
the array (2 ports comprise of one sample replicate on
the array). Thus, the samples run as duplicates were
only loaded into 4 ports of the array. Thermal cycling
conditions included a 50°C step for 2 minutes, denatura-
tion for 10 min at 94°C followed by 40 cycles consisting
of 2 steps: 97°C for 30 seconds and 59.7°C for 1 minute
for annealing and extension.
The raw data from the Prism 7900HT sequence detec-
tion system was imported into the Real-Time StatMi-
ner™ software for statistical analysis of the data. Among
the endogenous reference genes included on the array
(18S ribosomal gene; UBC, b2 microglobulin), UBC and
b2 microglobulin were chosen after visualizing the glo-
bal Ct value distribution, for normalizing the data (Sup-
plementary figure 1). The TLDA assays were run at
LabIndia Instruments Pvt Ltd laboratories at Gurgaon,
New Delhi.
Immunohistochemistry (IHC)
IHC was done for MMP3 protein expression in 5
Normal cervical tissue, 30 dysplasias of varying grade
(CIN1 - 11; CIN2 - 8; CIN3/CIS - 11) and 27 invasive
cervical cancers. A 3 layered ABC technique was used
as described previously [15]. MMP3, monoclonal anti-
body (Sigma Aldrich, India; cat no: M6552) was used at
a dilution of 1:75 and with wet antigen retrieval method.
Positive control (section from a pancreatic cancer) and
negative control (omission of primary antibody) were
included in each run. The slides were scored by SS and
TR independently and where discordant, jointly. The
scoring was based on percentage of tumour cells immu-
noreactive (negative - 0; <25% = 1; 25-50% - 2; 51 -
75% - 3; >75% - 4), intensity of immunoreactivity (nega-
tive - 0; + - 1; ++ - 2; +++ - 3) and the compartment
stained (cytoplasmic, nuclear or stromal). The scores
obtained were added and the threshold was set at above
the scores seen in the Normal cervical tissue (maximum
score seen in Normal cervical tissue was 8). Hence tis-
sues with a score of 9 or above were considered to over-
express MMP3.
p16 IHC was done as described previously [16] on 5
normal cervical tissue, 31 dysplasias of varying grades
(CIN1 - 12; CIN2 - 8; CIN3/CIS - 11) and 29 tumours.
Slides were scored as reported previously [16].
UBE2C IHC was done as above using wet autoclaving
with a hold time of 5 minutes. Rabbit UBE2C polyclonal
antibody (Millipore, USA - catalogue no: AB3861) was
used at 1 in 100 dilution. The scoring was done similar
to the scoring of MMP3 staining, with the maximum
s c o r es e e ni nn o r m a lc e r v i c a lt i s s u eb e i n g6 .H e n c ea
score of 7 or above was considered to be overexpression.
UBE2C in cervical cancer cell lines
Taqman Real time PCR was done for UBE2C levels in
SiHa, C33A, HeLa, ME180, BU25K and HEK293
(Human embryonic kidney cells) cell lines. GAPDH was
used to normalize the data.
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replaced by Serine, leading to loss of catalytic activity
[17] was introduced into SiHa cells, using Fugene 6
Transfection Reagent (Roche Applied Science) according
to the manufacturer’s instructions using a 3:2 Fugene/
DNA ratio. The effect on growth was assessed using the
MTS assay (Promega) in the SiHa wild type (WT), in
SiHa with pcDNA vector alone (SiHa pcDNA) and in
SiHa with dominant negative UBE2C (SiHa DN-
UBE2C).
Statistical analysis
Comparison between group means was assessed using a
one-way ANOVA and multiple-comparison correction
by Holm-Sidak method using Sigmaplot version 11.0.
Fisher’s exact test (2 tailed) was used to assess signifi-
cance of IHC immuno-reactivity between cancer and
dysplasias.
Results
The stage distribution of the invasive cancer cases was
as follows: IB - 2, IIA - 4, IIB - 18 and IIIB - 4. Twenty
seven of the tumours were Squamous cell carcinomas
(18 Large cell non-keratinizing, 5 large cell keratinizing
and 4 unspecified) and one was a poorly differentiated
carcinoma. Eighteen were HPV16 positive, 6 were
H P V 1 8p o s i t i v ea n d4w e r eH P V 1 6a n d1 8s u b t y p e
negative (but HPV positive). All the Normals were HPV
negative while one CIN1/2 and all the CIN3/CIS were
HPV16 positive.
Using different methods, as described above, genes
that were found to be differentially expressed between
the four classes (Normal, CIN1/2, CIN3/CIS and
Cancer) were identified. We did not use a Training
set and a Test set for the Class Prediction model but
used LOOCV for cross-validation and obtain the mis-
classification error. The list of genes significant by dif-
ferent methods of microarraya n a l y s i si sg i v e ni nt h e
Additional File 1 (AF1).
Sixty nine genes were selected for further validation by
RQ-PCR using the Taqman Low Density Array card
(TLDA) format (Additional File 2). These 69 genes
formed part of the 95 genes selected for analysis using
the TLDA format. The additional genes were those
which had been found to be differentially expressed
between the responders and non-responders to radio-
therapy only treatment. Apart from the mandatory
endogenous 18S rRNA included in the TLDA cards,
based on the microarray data, UBC and b2 microglobu-
lin, were included as additional endogenous reference
genes.
Two of the samples CXL19-hov160 and CXM024-
hov210 which had worked in microarray did not amplify
satisfactorily in the RQ-TLDA assay and had to be
removed from further analysis. In addition, RPS3A gene
did not amplify in any of the samples.
The RQ values after calibrating with the Normal sam-
ples (Mean) for all the 94 genes showed 8 additional
genes to be overexpressed; 4 (ASB16, CCL18, FST,
THOC6) in Cancers, 1 (KLK9) in CIN3/CIS and 3
(RASSF6, TMEM123 and GLB1L3) in CIN1/2 samples.
These 8 genes had initially been chosen for validation of
the differentially expressed genes between responders
and non-responders to radiotherapy. After excluding the
genes which did not amplify, we now had 76 genes for
further analysis.
Of the 31 genes which had been selected based on a
greater than 2 fold difference between cancer versus
CIN1/2 & Normal, 28 were concordant between the
microarray data and the RQ-RT-PCR (Concordant rate
of 90%). Three of four genes selected based on higher
level of expression in Normals compared with all other
classes showed concordance between the different meth-
ods of analysis. In the case of CIN1/2, concordance was
seen in 6/7 genes (86%). However, with CIN3, this
dropped to 41% (11/27). In four additional genes, there
was a two fold greater difference between CIN3/CIS and
Normal but not with CIN1/2. The overall concordance
rate between the microarray data and the RQ-RT-PCR
was 70% (48/69).
The list of genes validated and found to have a greater
than 2 fold difference compared to the Normal, in the 3
different classes (Cancer, CIN3/CIS and CIN1/2) is
given in Table 1. Figure 1 provides the fold change rela-
tive to Normal for these genes.
The genes were grouped on the basis of whether or
not they were known to be involved in cervical tumori-
genesis (Tables 2 and 3). Gene Ontology mapping was
done using Babelomics software [18], which showed an
over-representation of genes involved in cell cycle, cell
division, catabolic process and multi-cellular organismal
metabolic process. The genes identified to be differen-
tially expressed were then analysed for specific pathways
of relevance by manual curetting of data from published
literature and online databases. The genes were grouped
under the following categories: 1. Cell cycle regulatory
genes (n = 13); 2. Interferon induced genes (n = 5); 3.
Ubiquitin pathway (n = 5); 4. Myc Pathway [19] (n =
12); 5. HPV-E6/E7 related genes [20] (n = 14); 6. RNA
targeting genes (n = 3) (details are given in Additional
File 3). In addition, 40 genes in our list were found to
be potentially regulated by p53 family of genes [21]
(Additional File 4). Using GeneGo’s Metacore software
(Trial version) (url: http://www.genego.com), the rela-
tionship of our validated genes with known Transcrip-
tion factors was analyzed. Based on this and from the
manually curetted information, we then attempted to
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mation on the gene interactions.
Using IHC, we studied the protein expression for
MMP3 in 5 normal cervical tissues, 30 dysplasias of
varying grades and 27 invasive cancers. Using a semi-
quantitative scoring systema n dac u t - o f ft h r e s h o l ds e t
based on the normal cervical tissue staining, 6/30 dys-
plasias and 11/27 invasive cancers were found to overex-
press MMP3 protein (Figure 3A). Among the patients
Table 1 Rq Values For The Genes Relative To Normal
TUMOR CIN3 CIN1 p
VALUE
ADJUSTED
p VALUE
CANCER
AGRN 4.43991 0.87936 1.30918 1.95E-06 1.22E-05
APOBEC3B 28.7531 5.01379 8.85884 0.00203 0.00465097
ASB16 11.8884 2.29963 1.66354 0.01969 0.033056418
C20orf42/
FERMT1
4.39903 2.94499 5.01419 3.16E-05 0.000123866
CCL18 7.20321 1.62004 0.0723 0.00717 0.013221849
CDC20 19.7377 13.8732 3.55849 2.98E-12 2.80E-10
CDC25B 3.2086 1.52287 1.4008 6.66E-05 0.000231975
CDH3 29.0774 13.1587 10.9346 4.79E-08 6.44E-07
CDKN2A 274.282 731.037 21.5102 2.75E-09 6.46E-08
CKS1B 2.13404 1.45612 0.69024 0.43779 0.587807354
CKS2 8.23126 6.96362 1.77975 2.75E-10 1.29E-08
COL7A1 7.1098 2.76264 5.36018 2.29E-06 1.34E-05
DTX3L 2.02309 1.16971 1.156 0.00341 0.006842128
FST 3.82365 0.71799 1.70232 0.04615 0.06996509
IGF2BP2 2.47182 0.45821 2.32119 0.13561 0.176463734
IL8 5.09435 0.86174 0.12926 0.00384 0.007519964
INDO 9.6009 1.25824 0.94788 0.00063 0.001856627
ISG15 13.9329 2.06597 2.16239 3.44E-07 3.23E-06
ISG20 2.11654 0.49943 0.3666 0.05737 0.080570517
KRT17 20.0558 3.92122 1.04329 1.42E-08 2.50E-07
LAMB3 13.6515 2.4397 4.96423 5.70E-06 2.82E-05
MCM4 3.85854 1.34001 1.07006 0.0004 0.001222519
MCM6 2.38446 1.48791 0.87143 0.00451 0.00865803
MELK 6.63844 5.96901 2.12471 1.75E-06 1.17E-05
MMP1 125.944 2.52253 0.1402 4.30E-07 3.67E-06
MMP3 40.0729 0.30275 0.03493 4.44E-05 0.000166947
NUP210 4.14316 3.45836 1.34658 0.00106 0.002782383
PLOD2 2.41806 2.21483 1.11276 0.00709 0.013221849
SLC16A1 6.71744 2.80011 3.82016 0.00092 0.002541873
SLC2A1 5.69119 3.34455 2.93698 0.00079 0.002242462
SMC4 3.93197 3.28125 1.65161 1.72E-05 7.68E-05
STAT1 9.1538 2.15413 3.16578 9.84E-05 0.000330443
THOC6 2.73991 1.63077 1.93361 0.08808 0.197141325
TK1 13.4525 7.11209 2.42871 4.91E-10 1.54E-08
TOP2A 2.72523 1.82496 1.08463 0.00164 0.003959245
UBE2C 14.054 12.1512 4.10121 3.51E-06 1.83E-05
C20orf114 0.00068 0.01085 0.1082 0.0002 0.000644363
FCGBP 0.01637 0.11346 0.23912 4.98E-05 0.00017995
RGS5 0.0692 0.40561 0.58543 9.63E-07 6.96E-06
RPL10A 0.42083 0.89019 1.54046 0.01077 0.019108208
RPL13A 0.39404 0.62725 0.96561 0.00199 0.00465097
SPINK5 0.00677 0.0817 1.38502 9.33E-06 4.39E-05
TFF3 0.00108 0.02275 0.23349 3.40E-07 3.23E-06
TPD52L1 0.26451 1.71067 1.8713 0.00218 0.004873472
Table 1 Rq Values For The Genes Relative To Normal
(Continued)
CIN3
CALML5 0.51194 10.2307 5.18399 0.00709 0.05123751
CCNB1 10.6825 10.44 2.79343 0.0175 0.090329125
CCNB2 6.74715 7.52496 2.54768 0.00064 0.008554526
EBP 2.05888 5.0445 3.49571 0.00027 0.008554526
FLJ44635 1.40964 6.98147 3.89307 0.22913 0.365061765
KLK9 11.7606 30.8271 26.324 0.01049 0.065711523
NUSAP1 1.92037 6.57218 1.75057 0.00533 0.049372841
PCNA 1.76308 2.64579 0.92838 0.01586 0.090329125
CIN1
B4GALT1 1.29547 0.63469 2.21031 0.05915 0.166469075
CAPNS2 0.32306 1.98671 2.3676 0.01723 0.095298509
CD36 0.71359 10.6158 14.142 0.00889 0.052209988
CRNN 0.00053 0.40085 12.1177 0.00104 0.027439506
CSTB 0.17911 0.90884 4.5624 0.00263 0.029029697
CXCL14 0.09773 1.49396 11.7379 0.07384 0.182664861
DAPL1 0.03534 1.35468 6.09254 0.00067 0.027439506
DBI 0.40666 2.15767 3.98554 0.00469 0.031486868
DYNLL1 5.20441 4.20119 6.97185 0.07896 0.185551839
FBLN1 0.15796 0.34282 2.85624 0.05894 0.166469075
GJA1 0.16263 0.60199 3.58862 0.0017 0.029029697
GLB1L3 0.11823 0.47805 5.23721 0.04676 0.16283811
HEBP2 0.82928 1.50603 2.15449 0.03338 0.144693437
HOPX 0.04259 0.57251 2.37465 0.07856 0.185551839
KRT10 0.50079 7.42996 107.277 0.00309 0.029029697
KRTDAP 0.00637 0.61177 10.8535 0.00431 0.031486868
MAFB 1.18718 2.08998 4.15406 0.0029 0.029029697
RASSF6 2.55599 3.073 8.63768 0.00189 0.029029697
SLURP1 0.00845 0.56737 7.04202 0.00117 0.027439506
TMEM123 2.77691 1.00492 19.4085 0.03995 0.150195313
GENES WITH LESS THAN TWO FOLD DIFFERENCE IN THE 3
CLASSES
PARP14 1.61309 0.75545 0.6995 0.04808 0.071743665
RPS8 0.75787 0.87528 0.97209 0.59992 0.65977976
RPL9 1.34116 0.44416 0.59991 0.41918 0.49253415
TIMM8B 0.82901 1.51431 1.92649 0.55825 0.628406378
Gene symbols in bold italics indicate those which were not concordant
between microarray and RQ-RT-PCR analysis.
Rajkumar et al. BMC Cancer 2011, 11:80
http://www.biomedcentral.com/1471-2407/11/80
Page 5 of 14Figure 1 Relative quantitation levels of significant genes.
Table 2 Genes Identified as Up or Down-Regulated In Cervical Cancers For The First Time
S.
No:
GENE
SYMBOL
FUNCTION CANCERS WHEREIN UP-REGULATION REPORTED
1 AGRN Basement membrane component Hepatocellular carcinoma (HCC) [27], Synovial sarcoma [28]
2 CCL18 Attracts lymphocytes towards dendritic cell Gastric cancer [29]
3 CKS1B Cell cycle Breast cancer [30] etc.
4 COL7A1 Epithelial basement membrane organization Oesophageal cancer [31]
5 DNYLL1/DLC1 Inhibits neuronal nitric oxide synthase Breast cancer [32]
6 FERMT1 Cell adhesion; TGF-b signalling Lung and colon cancer [33]
7 FST Activin antagonist; inhibits synthesis and secretion
of FSH
Wilm’s tumour, Basal cell carcinoma [34]
8 IGF2BP2 Regulate translation of target mRNA Testicular cancer [35], HCC [36]
9 IL8 Inflammatory cytokine Several cancers; HR-HPV+VIN [37]
10 KLK9 Serine protease Bladder cancer [38], breast cancer [39]
11 MELK Leucine zipper kinase Colo-rectal cancer, lung cancer [40] , brain cancer [41]
12 PLOD2 Lysyl hydroxylase Glioblastoma [42]
13 RASSF6 Tumour suppressor Low levels detected in HeLa cell line [43]
14 SLC16A1 Monocarboxylate transporter Neuroblastoma [44]
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Page 6 of 14Table 2 Genes Identified as Up or Down-Regulated In Cervical Cancers For The First Time (Continued)
15 SMC4 Chromosome condensation; DNA repair Breast cancer [45]
16 APOBEC3B RNA editing enzyme None to date
17 ASB16 Ubiquitin pathway None to date
18 NUP210 Nuclear pore complex None to date
19 THOC6 Splicesome associated protein None to date
20 TMEM123 Induces Pro-oncosis type cell death None to date
CIN3
1 CCNB2 Cell cycle Lung [46], pituitary tumours [47]
2 EBP ER Protein ALK+ Anaplastic large cell lymphoma [48]
3 NUSAP1 Microtubule associated protein Melanoma [49]
4 CALML5 Calcium binding protein Psoriasis [50]
5 FLJ44635 TPT1-like protein None to date
CANCERS WHEREIN DOWN-REGULATION REPORTED
1 C20ORF114 Innate immunity Nasopharyngeal cancer [51]
2 CRNN Tumour suppressor Tongue cancer [52]
3 CSTB Thiol proteinase inhibitor; anti-metastatic Laryngeal cancer [53]
4 DBI Intracellular carrier for Acyl-COA esters Overexpressed in Brain tumours [54]
5 FCGBP Maintenance of mucosal surface Prostate [55]
6 HOPX Tumour suppressor Choriocarcinoma [56] and lung cancer [57]
7 SLURP1 Anti-tumour; anti-angiogenic Hypopharyngeal cancer; Can induce apoptosis in Kaposi’s sarcoma [58]
8 SPINK5 Serine protease inhibitor Tongue cancer [59]
9 TFF3 Protect mucosa Down-regulated in highly invasive colon cancers [60] and in thyroid
cancers [61]
10 CAPNS2 Thiol protease None to date
11 DAPL1 Epithelial differentiation None to date
12 GLB1L3 Galactosidase beta1 like None to date
13 HEBP2 Heme binding protein None to date
14 KRTDAP Keratinocyte differentiation None to date
Table 3 Genes Known To Be Up or Down-Regulated In Cervical Cancers Found Also In Our Study
UP-REGULATED
S
NO:
GENE
SYMBOL
FUNCTION REFERENCES
1 CCNB1 Cell cycle Overexpressed in cervical cancers [62]
2 CDC20 Cell cycle HR-HPV E2 interaction [63]
3 CDC25B Cell cycle FOXM1 increases Cyclin B1, CDC25B, Cyclin D1 in cervical cancers [64]
4 CDH3 Cell adhesion P-Cadherin predominant cadherin in high grade cervical dysplasia [65]
5 CDKN2A Cell cycle Overexpressed in high grade dysplasia and invasive cancers [66]
6 CKS2 Cell cycle Overexpressed in cervical cancer [67]
7 DTX3L Ubiquitin pathway Overexpressed in cervical cancer [68]
8 INDO/IDO1 Immuno-suppression Role in inducing immunosuppression in the tumour milleu [69]
9 ISG15/G1P2 Ubiquitin like protein Over-expressed in invasive cancer [70]
10 ISG20 Exonuclease with higher affinity for RNA Up-regulated by HPV E6 [71]
11 KRT17 Intermediate filament; marker for
epithelial “stem cells”
Overexpressed in cervical cancer [72]
12 LAMB3 Basement membrane protein HR-HPV-E6 inhibits miR-218 which regulates LAMB3 [73]
13 MCM4 Cell cycle Widely expressed in cervical cancers [74]
14 MCM6 Cell cycle Over-expressed in cancer [75]
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Page 7 of 14Table 3 Genes Known To Be Up or Down-Regulated In Cervical Cancers Found Also In Our Study (Continued)
15 MMP1 Breakdown of extracellular matrix Overexpressed in cervical cancers [76]
16 MMP3 Breakdown of extracellular matrix Metastatic lymphnodes in cervical cancer harbour MMP3 positive tumour cells [77];
Increased in stroma in cancers [78]
17 SLC2A1 Glucose transporter Expressed in CIN and invasive cervical cancers [79]
18 STAT1 Transcription activator Overexpressed in cervical cancers [80]
19 TK1 Thymidine kinase Up-regulated in invasive cancers [81]
20 TOP2A Topoisomerase Overexpressed in cervical cancers [82]
21 UBE2C Ubiquitin pathway Overexpressed in cervical cancer [76]
CIN3
1 PCNA Cell cycle Major up-regulation of PCNA upon progression to CIN3 [83]
DOWN-REGULATED
1 FBLN1 Cell adhesion; tumour suppressor E6 binds to Fibulin1 and modulates its activity [84]
2 CD36 Cell adhesion CD36 down-regulated in high grade dysplasias and cancer [85]
3 CXCL14 Immunoregulatory cytokine Down-regulated in cervical and head and neck cancers [86]
4 GJA1 Gap junction Down-regulated in CIN3 and invasive cancers [87]
5 KRT10 Intermediate filament Down-regulated in invasive cancer [72]
Figure 2 Inter-relationship of our validated genes with known Transcription factors and E6 & E7 protein. Bold arrows indicate
stimulatory effect; dotted arrows indicate inhibitory effect. Dot-Dash arrow refers to unknown effect.
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Page 8 of 14whose tumours had been treated only with radical
radiotherapy and had been followed up for a minimum
period of 3 years, over-expression was seen in a greater
number of tumours that failed treatment (6/9) com-
pared to those free of disease at 3 years (2/12) (p =
0.03). p16 was found to be overexpressed in 19 of 31
dysplasias of varying grade and in 27/29 cancers (p =
0.005) (Figure 3B).
Using IHC, we found UBE2C to be overexpressed in
28/32 cancers, 2/11 CIN3/CIS and none of the CIN1 or
2 (Fisher’s exact test p = 2.2 e
-11) (Figure 3C). Using RQ
RT-PCR, UBE2C was found to be overexpressed by
more than 2 fold in SiHa, HeLa, C33A and ME180 rela-
tive to the HEK293 cells (Figure 4A). The growth of
SiHa cells transfected with dominant negative UBE2C
was significantly reduced at 48 and 72 hours compared
to SiHa WT and SiHa transfected with pcDNA vector
alone (p < 0.001) (Figure 4B).
Discussion
There was good overall concordance between the micro-
array and the RQ-RT-PCR data. The lower concordance
rate seen with the CIN3/CIS may be due to the addi-
tional CIN3 sample processed directly using RQ-RT-
PCR. The relative quantitation values with and without
the additional sample is given as Additional File 5. The
concordance rate between microarray and semi-quanti-
tative RT-PCR in the study by Gius et al [8] was less
than 50%, using the standard microarray data analysis
package.
There were several instances, wherein, a small differ-
ence in Microarray (above the 2 fold mandatory criteria)
sometimes translated to large differences with RQ-RT-
PCR (e.g. p16, MMP1, MMP3) and vice versa (e.g.
CD36). This reinforces the point about the limitation of
the microarray technique and it does emphasize the need
for further validation, using assays like RQ-RT-PCR.
HPV16 was the predominant subtype seen in the inva-
sive cancers and CIN3/CIS. However, we did not look
for all the high risk subtypes and hence cannot exclude
multiple subtype infection. Four of the cancers were
HPV positive but HPV16 and 18 negative, suggesting
that other high risk subtypes could be involved. None of
the normal cervical tissues were HPV positive.
The genes that were for the first time, found to be
over-expressed in cervical cancers compared to Normal
cervix, is given along with information in which other
cancers they have been reported to be overexpressed
(Table 2A). Our study, for the first time, has identified
20 genes to be up-regulated in cervical cancers and 5 in
C I N 3 ;1 4g e n e sw e r ef o u n dt ob ed o w n - r e g u l a t e d .I n
addition, 26 genes identified by other studies, as to play-
ing a role in cervical cancer, were also confirmed in our
study. UBE2C, CCNB1, CCNB2, PLOD2, NUP210,
MELK, CDC20 were overexpressed in tumours and in
CIN3/CIS relative to both Normal and CIN1/CIN2, sug-
gesting that they could have an important role to play
in the early phase of tumorigenesis. Among the genes
which were up-regulated in cancers compared to that of
Figure 3 Immunohistochemical staining for MMP3 (3A), p16
(3B) and UBE2C (3C) in invasive cancers (Magnification × 200).
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Page 9 of 14Normal, CIN1/2 or CIN3/CIS, IL8, INDO, ISG15,
ISG20, AGRN, DTXL, MMP1, MMP3, CCL18, TOP2A
A N DS T A T 1a r el i k e l yt op l a ya ni m p o r t a n tr o l ei nt h e
progression of the disease.
STAT1 gene has a bi-phasic level, a rise in CIN1/2,
drop in CIN3/CIS and a significant rise in invasive
cancers. STAT1 has been considered generally to be a
tumour suppressor, while STAT3 and STAT5 are
known to be proto-oncogenes. However, recent studies
have shown STAT3 to have both oncogenic and tumour
suppressor function [22]. It could be that in cervical
cancer, STAT1 may be protective in the early phase of
Figure 4 UBE2C experiment data. 4A: RQ of UBE2C in cervical cancer cell lines. Fold change relative to HEK293 cells. 4B: Growth curve for SiHa
WT cells, SiHa cells transfected either with pcDNA alone or with Dominant negative UBE2C. ★ Denotes a statistically significant change (p < 0.001).
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Page 10 of 14HPV infection but could function as a proto-oncogene
in the invasive stages of the disease. Highly invasive
melanoma cell lines had high levels of STAT1 and
c-myc [23].
The study by Lessnick et al., [24] showed that introduc-
tion of the potentially oncogenic EWS-FLI transcript into
the fibroblasts, resulted in growth arrest rather than
transformation. Knocking out p53 using HPV E6 helped
overcome the growth arrest but was not sufficient to
induce malignant transformation. The study used micro-
array to identify genes differentially expressed between
the EWS-FLI transfected and the mock transfected cell
line and found several genes related to growth promotion
down-regulated. Our study had several genes [19] over-
lapping with theirs. Thirteen genes from our study were
f o u n dt ob eH P VE 6 / E 7r e l a t e dg e n e s [ 2 0 ]a n d4 0o ft h e
genes in our list were found to be potential p53 Family
Target genes[21] (Additional File 3). In addition, there
were 12 myc regulated genes, (MYC Cancer database at
http://www.myc-cancer-gene.org/) of which CSTB which
has been reported to be down-regulated by myc, was
down-regulated in CIN3/CIS and in Cancer [19].
p16 gene, a tumour suppressor has been reported to be
over-expressed in dysplasias and invasive cancer of the
cervix. Several studies have tried to use this as a marker
in the PAP smears for more reliable interpretation of the
smear. von Knebel’s group from Germany [25], had
developed an ELISA to detect p16 in the cervical cell
lysates, and reported a 96% sensitivity to pick up high
grade dysplasias. Subsequently, the p16 ELISA assay was
compared with Hybrid Capture 2 and was found to have
comparable sensitivity and a slightly better specificity
(46.9% versus 35.4%) [26]. Our RQ-RT-PCR data shows a
gross over-expression of p16 in the CIN3 and invasive
cancers (>250 fold). In our series of dysplasias and can-
cers, p16 protein was found to be overexpressed in inva-
sive cancers compared to the dysplasias.
Figure 2 shows the inter-relationship of our genes
with E6 and E7 protein and other known Transcription
factors including p53, E2F, c-myc, B-MYB and c-Jun.
The important genes in our list MELK, ISG15, STAT1,
IL8, MMP1 and MMP3, could be playing critical roles
in the tumorigenic pathway and could be potential tar-
gets for newer therapies.
UBE2C is an E2 enzyme involved in the process of
ubiquitination. Townsley et al. [17] had developed a
dominant negative UBE2C which lacks the catalytic
activity. When the dominant negative UBE2C was
expressed in SiHa cells, which have nearly 4 fold greater
levels of UBE2C compared to HEK293 cells, it produced
a significant growth inhibition (Figure 4B), indicating
that the dominant negative UBE2C is competing with
the wild type UBE2C, and can interfere with cell
proliferation. Additional studies will be required to
understand the mechanism by which this effect occurs.
Conclusion
Our study has helped identify newer genes which could
play a role in the cervical tumorigenesis and could offer
the potential of developing newer diagnostic markers
and therapeutic targets. We have confirmed over-
expression of MMP3, UBE2C and p16 in tumours, by
IHC. This will need to be validated further in a larger
series of tumours and dysplasias. UBE2C will need to be
studied further to assess its potential as a target for the
treatment of cervical cancer.
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